Want to see HK:2496 full AI Analyst Report?
2496 Stock Chart & Stats
HK$3.69
-HK$0.11(-2.89%)
At close: 4:00 PM EDT
HK$3.69
-HK$0.11(-2.89%)
Day’s Range― - ―
52-Week RangeHK$0.96 - HK$8.50
Previous CloseN/A
Volume200.00
Average Volume (3M)933.00
Market Cap
HK$715.30M
Enterprise ValueHK$719.78M
Total Cash (Recent Filing)HK$100.11M
Total Debt (Recent Filing)HK$127.81M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding179,479,110
10 Day Avg. Volume80
30 Day Avg. Volume933
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)-26.32
Price to Sales (P/S)21.44
P/FCF Ratio-62.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnOperating and free cash flow losses narrowed sharply in 2025 versus 2024, showing management tightened spending or working-capital relief. This durable improvement reduces near-term financing pressure and extends runway, increasing the chance of reaching cash neutrality with further discipline.
Historical High Gross MarginsThe company has demonstrated the ability to achieve very high gross margins historically, indicating underlying product or IP economics that can be highly profitable if revenue stabilizes. This structural capability supports long-term margin recovery if operations scale or product mix improves.
Lean Operating HeadcountA relatively small workforce suggests a lean cost base and operational flexibility, enabling faster expense reductions if revenues remain weak. For a biotech firm reliant on R&D and partnerships, a compact team can preserve cash and pivot resources without large fixed-cost commitments.
Bears Say
Sharp Revenue CollapseA greater-than-50% revenue decline in the most recent year signals durable demand or execution problems. Such a steep drop undermines unit economics, makes scaling difficult, and lengthens the timeline to profitability even if cost controls are implemented, raising structural recovery risk.
Gross Margin DeteriorationA dramatic collapse in gross margin indicates loss of high‑value revenue streams, pricing pressure, or unfavorable cost mix. Restoring premium margins may require product repositioning or new approvals, meaning margin recovery is a substantial operational challenge rather than a short-term fluctuation.
Balance-sheet Solvency RiskNegative equity and materially higher debt materially restrict financial flexibility and capacity to raise secured funding. This structural solvency deterioration increases refinancing risk, may dilute shareholders if capital is raised, and limits ability to fund R&D or commercialization without external support.
Wuhan YZY Biopharma Co., Ltd. Class H News
2496 FAQ
What was Wuhan YZY Biopharma Co., Ltd. Class H’s price range in the past 12 months?
Wuhan YZY Biopharma Co., Ltd. Class H lowest stock price was HK$0.96 and its highest was HK$8.50 in the past 12 months.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s market cap?
Wuhan YZY Biopharma Co., Ltd. Class H’s market cap is HK$715.30M.
When is Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date?
Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 25 days.
How were Wuhan YZY Biopharma Co., Ltd. Class H’s earnings last quarter?
Wuhan YZY Biopharma Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported -HK$0.146 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.146.
Is Wuhan YZY Biopharma Co., Ltd. Class H overvalued?
According to Wall Street analysts Wuhan YZY Biopharma Co., Ltd. Class H’s price is currently Overvalued.
Does Wuhan YZY Biopharma Co., Ltd. Class H pay dividends?
Wuhan YZY Biopharma Co., Ltd. Class H does not currently pay dividends.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate?
Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wuhan YZY Biopharma Co., Ltd. Class H have?
Wuhan YZY Biopharma Co., Ltd. Class H has 179,479,110 shares outstanding.
What happened to Wuhan YZY Biopharma Co., Ltd. Class H’s price movement after its last earnings report?
Wuhan YZY Biopharma Co., Ltd. Class H reported an EPS of -HK$0.146 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuhan YZY Biopharma Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2496
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuhan YZY Biopharma Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.62%
Trailing 12-Months
Company Description
Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Technical Analysis
Brii Biosciences Limited
―
3D Medicines, Inc.
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Sunho Biologics,Inc.
―